Table 1.
Clinical characteristics of patients and controls.
| AAV | HC | RA | |
|---|---|---|---|
| ANCA-pos. patients (n) | 26 | 20 | 7 |
| Proteinase 3 + | 19 (73%) | ||
| Myeloperoxidase + | 7 (27%) | ||
| Seropositive (RF and anti-CCP) | 7 (100%) | ||
| Sex | |||
| Female | 17 (65%) | 14 (70%) | 5 (71%) |
| Male | 9 (35%) | 6 (30%) | 2 (29%) |
| Age (years, mean ± SD) | 61.7 ± 3.4 | 56,2 ± 5.2 | 68.2 ± 6.4 |
| Disease duration (years, mean ± SD) | 6.4 ± 1.3 | ||
| Mean CRP (mg/l, mean ± SD) | 12.6 ± 2.8 | 7.3 ± 3.4 | |
| DAS28-CRP | 2.5 ± 0.2 | ||
| Organ involvement | |||
| Ear, nose, and throat (ENT) | 17 (66%) | ||
| Lungs | 18 (69%) | ||
| Kidneys | 17 (66%) | ||
| Skin | 5 (19%) | ||
| Joints | 8 (31%) | ||
| Peripheral nerves | 7 (27%) | ||
| Medication at blood drawing | |||
| untreated | 2 (8%) | 0 (0%) | |
| Prednisone | 17 (65%) | 1 (14%) | |
| Prednisone dose (median ± SD) | 4.5 mg ± 4.1 | 0.2 mg ± 0.1 | |
| Rituximab | 12 (46%) | 0 (0%) | |
| Methotrexate | 5 (19%) | 5 (71%) | |
| Azathioprin | 4 (15%) | 0 (0%) | |
| Cyclophosphamide | 2 (8%) | 0 (0%) | |
| Leflunomide | 2 (8%) | 0 (0%) | |
| Mycophenolat mofetil | 2 (8%) | 0 (0%) | |
| Hydroxychloroquine | 1 (4%) | 2 (29%) |